Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 6/20 | 0.62 |
| ▸ | NPY1R | P25929 | 3/20 | 0.61 |
| ▸ | NPY2R | P49146 | 3/20 | 0.61 |
| ▸ | NPY4R | P50391 | 3/20 | 0.61 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.61 |
| ▸ | IL1RN | P18510 | 1/20 | 0.56 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31619568 | 0.97 | UTS2R (0.63) | GHSRNPY1RNPY2RNPY4RUTS2R | |
| SCHEMBL29937688 | 0.95 | GHSR (0.65) | GHSRUTS2R | |
| SCHEMBL29577431 | 0.94 | NPY1R (0.66) | GHSRNPY1RNPY2RNPY4RUTS2R | |
| SCHEMBL29578675 | 0.94 | NPY1R (0.66) | GHSRNPY1RNPY2RNPY4RUTS2R | |
| SCHEMBL29508662 | 0.93 | GHSR (0.63) | GHSRNPY1RNPY2RNPY4RIL1RN | |
| SCHEMBL29896929 | 0.93 | GHSR (0.63) | GHSRNPY1RNPY2RNPY4RERAP2 | |
| SCHEMBL31731732 | 0.93 | GHSR (0.62) | GHSRNPY1RNPY2RNPY4RUTS2R | |
| SCHEMBL29938255 | 0.93 | GHSR (0.64) | GHSRUTS2R | |
| SCHEMBL29508714 | 0.92 | GHSR (0.64) | GHSRNPY1RNPY2RNPY4RUTS2R | |
| SCHEMBL29508679 | 0.92 | GHSR (0.64) | GHSRNPY1RNPY2RNPY4RUTS2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025043563-A1 | PEPTIDE TARGETING SOMATOSTATIN RECEPTOR, DRUG CONJUGATE AND USE THEREOF | 主流源生物科技(上海)有限公司 | 2025-03-06 | — | — | WO | claimed |
| WO-2025043563-A1 | PEPTIDE TARGETING SOMATOSTATIN RECEPTOR, DRUG CONJUGATE AND USE THEREOF | 主流源生物科技(上海)有限公司 | 2025-03-06 | — | — | WO | disclosed |
| US-20240374732-A1 | STABLE FORMULATIONS FOR RADIONUCLIDE COMPLEXES | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2024-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240374732-A1 | STABLE FORMULATIONS FOR RADIONUCLIDE COMPLEXES | SLC40A1, SLC7A11, GYPA | GHSR 977/4885NPY1R 4279/4885NPY2R 4259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.